There is also evidence for growth factor expression alterations such as in stromal derived factor-1 and BAFF (B cell activating factor) which may also alter myelopoiesis after rituximab [18], and late onset neutropenia seems more associated with various Fc receptor polymorphisms [19]. Here, TNFSF13B is linked to neutropenia.